Multiple organ failure after an overdose of less than 0.4 mgkg of colchicine: Role of coingestants and drugs during intensive care management

Clinical Toxicology

Volumn 48, Issue 8, 2010, Pages 845-848

  Montiel, Virginie ^a   Huberlant, Vincent ^a   Vincent, Marie Françoise ^a   Bonbled, Frédéric ^a   Hantson, Philippe ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Atorvastatin; Cholestatic liver failure; Colchicine poisoning; Hyperammonemia; Hypertriglyceridemia; Propofol infusion syndrome; Rhabdomyolysis

Indexed keywords

ATORVASTATIN; COLCHICINE; CYTOCHROME P450 3A4; DICLOFENAC; FUROSEMIDE; GLYCOPROTEIN P; IBUPROFEN; PROPOFOL;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CLINICAL FEATURE; DEATH; DISEASE SEVERITY; DRUG OVERDOSE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERAMMONEMIA; HYPERTRIGLYCERIDEMIA; HYPOXEMIA; INGESTION; INTENSIVE CARE; LIVER FAILURE; MORTALITY; MULTIPLE ORGAN FAILURE; MUSCLE INJURY; PANCYTOPENIA; PROPOFOL INFUSION SYNDROME; REYE SYNDROME; RHABDOMYOLYSIS; SEDATION; SEPSIS; SYMPTOM;

EID: 77958601194     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2010.509101     Document Type: Article

References (13)

1. Bismuth C, Baud F, Dally S. Standardized prognosis evaluation in acute toxicology: its benefit in colchicine, paraquat, and digitalis poi-soning. J Toxicol Clin Exp 1986; 6:33-38.
2. Borron SW, Scherrmann JM, Baud FJ. Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Hum Exp Toxicol 1996; 15:885-890.
3. Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Indentification of CYP3A4 as the major isoform responsible for colchicine demethyla-tion. Biochem Pharmacol 1997; 53:111-116.
4. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38:411-419.
5. Tang W. The metabolism of diclofenac. Enzymology and toxicology perspectives. Curr Drug Metab 2003; 4:319-329.
6. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008; 38:1240-1251.
7. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in sta-tin drug interactions. Pharmacotherapy 2006; 26:1601-1607.
8. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and lit-erature review. Pharmacotherapy 2004; 24:1784-1792.
9. Tufan A, Dede DS, Cavus S, Altintas ND, Iskit AB, Topeli A. Rhab-domyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother 2006; 40:1466-1469.
10. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C.
11. Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, Perl A. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol 2008; 1:129-131.
12. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003; 29:1417-1425.
13. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndrome. Cell Biochem Funct 2008; 26:741-746.